APELLIS PHARMACEUTICALS INC's ticker is APLS and the CUSIP is 03753U106. A total of 262 filers reported holding APELLIS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.39 and the average weighting 0.4%.
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Octagon Capital Advisors LP | 3,130,000 | $119,065,200 | 18.29% |
| EcoR1 Capital, LLC | 10,899,859 | $414,630,636 | 13.99% |
| Ally Bridge Group (NY) LLC | 181,805 | $6,915,862 | 8.12% |
| Avoro Capital Advisors LLC | 11,111,111 | $422,666,662 | 6.59% |
| ACUTA CAPITAL PARTNERS, LLC | 244,484 | $9,300,171 | 6.23% |
| Iron Triangle Partners LP | 880,000 | $33,475,200 | 4.89% |
| Cormorant Asset Management, LP | 2,000,000 | $76,080,000 | 4.44% |
| Octagon Capital Advisors LP | 675,000 | $25,677,000 | 3.94% |
| Logos Global Management LP | 750,000 | $28,530,000 | 3.81% |
| Boxer Capital, LLC | 1,726,000 | $65,657,040 | 3.50% |
| Logos Global Management LP | 650,000 | $24,726,000 | 3.30% |
| Artal Group S.A. | 1,664,572 | $63,320 | 2.72% |
| Octagon Capital Advisors LP | 400,000 | $15,216,000 | 2.34% |
| Ghost Tree Capital, LLC | 185,000 | $7,037,400 | 2.31% |
| Slate Path Capital LP | 2,068,000 | $78,666,720 | 2.19% |
| 683 Capital Management, LLC | 576,000 | $21,911,040 | 1.70% |
| Frazier Life Sciences Management, L.P. | 614,043 | $23,358,196 | 1.55% |
| Velan Capital Investment Management LP | 50,000 | $1,902,000 | 1.53% |
| Affinity Asset Advisors, LLC | 130,000 | $4,945,200 | 1.39% |
| Ikarian Capital, LLC | 2,365 | $8,996,460 | 1.08% |
External links
This page lists APELLIS PHARMACEUTICALS INC's shareholders in Q3 2023. To view APELLIS PHARMACEUTICALS INC's shareholder history, click here.